<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365300">
  <stage>Registered</stage>
  <submitdate>13/11/2013</submitdate>
  <approvaldate>20/11/2013</approvaldate>
  <actrnumber>ACTRN12613001279718</actrnumber>
  <trial_identification>
    <studytitle>Prothrombinex-VF vs Fresh Frozen Plasma for the treatment of bleeding post cardiopulmonary bypass</studytitle>
    <scientifictitle>For patients who experience bleeding after cardiopulmonary bypass, will treatment with Prothrombinex VF as compared to treatment with Fresh Frozen Plasma, decrease the rate of red cell and platelet transfusions? </scientifictitle>
    <utrn>U1111-1150-2119</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-surgical bleeding after cardiopulmonary bypass</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Human 3 Factor Prothrombin complex concentrate (Prothrombinex VF) 25IU/kg IV bolus for the first line treatment of non surgical bleeding post cardiopulmonary bypass.</interventions>
    <comparator>Active control: Fresh Frozen Plasma 15ml/kg bolus IV as first line treatment for the treatment of non-surgical bleeding post cardiopulmonary bypass.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The composite end point of those patients receiving either allogeneic red blood cells or platelets after 15ml/kg FFP or Prothrombinex 25IU/kg</outcome>
      <timepoint>Up to 24 hours post operation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The total cost of treatment following randomisation, which will include, drugs, procedures, imaging, length of stay in ICU and hospital.  We will also include best estimation of blood product costs.</outcome>
      <timepoint>During hospital stay</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of thrombotic complications defined by CHADx groups:
5.2 (pulmonary embolism) and 5.8 Venous thrombosis/embolism(not progressing to PE) 
Assessment will be clinical and based on discharge coding.</outcome>
      <timepoint>At hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory indices (P:F ratios)</outcome>
      <timepoint>at 6 and 12 hrs post op</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall mortality</outcome>
      <timepoint>at 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of stay in ICU and Hospital</outcome>
      <timepoint>At discharge from hospital</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chest drain output</outcome>
      <timepoint>6 and 24 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ICU arrival haemoglobin</outcome>
      <timepoint>On ICU arrival</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total surgical red cell loss (Mercuriali formula)</outcome>
      <timepoint>Post operative day 5</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients undergoing cardiac surgery requiring cardiopulmonary bypass and determined to have non surgical bleeding post heparin reversal.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>The following patient groups will be excluded:
1.Patients with pre-existing bleeding diatheses
2.Patients receiving Prothrombinex or FFP less than 5 days before CPB
3.Patients receiving heart or lung transplant
4.Patients having implantation of ventricular assist devices (VADs)
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>13/01/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>Fremantle Hospital and Health Service - Fremantle</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Perth Hospital</primarysponsorname>
    <primarysponsoraddress>Royal Perth Hospital
Wellington Street 
Perth
WA 6001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>WA State Health Research Advisory Committee</fundingname>
      <fundingaddress>SHRAC
C/o Research Development Unit
Department of Health
PO Box 8172 
Perth Business Centre, WA 6849</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A multi centre, randomised, active control, trial of 200 patients comparing Prothrombinex VF with Fresh Frozen Plasma (FFP) as first line treatment for non surgical bleeding after cardiopulmonary bypass.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Metro Health (Fremantle Hospital) HREC</ethicname>
      <ethicaddress>Alma St, Fremantle WA 6160</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>15/11/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Warren Pavey</name>
      <address>Department of Anaesthesia and Pain Medicine
Royal Perth Hospital
Wellington Street
Perth 
WA 6001
</address>
      <phone>+61 8 92241038</phone>
      <fax />
      <email>warren.pavey@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Warren Pavey</name>
      <address>Department of Anaesthesia and Pain Medicine
Royal Perth Hospital
Wellington Street
Perth 
WA 6001
</address>
      <phone>+61 8 9224 1038</phone>
      <fax />
      <email>warren.pavey@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Warren Pavey</name>
      <address>Department of Anaesthesia and Pain Medicine
Royal Perth Hospital
Wellington Street
Perth 
WA 6001
</address>
      <phone>+61 8 9224 1038</phone>
      <fax />
      <email>warren.pavey@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>